Skip to main content

Member affordability

Working to keep prescription drug costs down for members and clients

Two patients reviewing prescription information at pharmacy

Improving health through affordability

At CVS Health®, we know that people are more likely to take their prescribed medications when they know they can afford them — and that can lead to better health outcomes. CVS Caremark®, our prescription benefit manager, is working with clients to translate the savings we secure for them into tangible savings for members.

2 ways we help lower out-of-pocket costs

CVS pharmacist working

Working behind the scenes

We negotiate directly with pharmaceutical companies, work with clients to help them get members affordable prices and partner with benefit consultants to help employers design more effective prescription drug coverage.

Providing real-time information

Members, their prescribing physicians and their pharmacists can see — in the moment — how much a drug will cost. This can help physicians and pharmacists find a clinically appropriate alternative medication at a lower cost, if necessary.

CVS pharmacist working on computer

Impacting specialty drug costs

As one of the nation’s largest providers of specialty pharmacy services, we negotiate with drug manufacturers for the most competitive prices. We also use personalized data and outreach to help reduce unnecessary health care costs.

Members’ out-of-pocket Rx costs

Featured icon alt text

>67%

Number of members who spent less than $100 out-of-pocket on prescription drugs

Female reviewing prescription information from CVS Pharmacy

Keeping an eye on Rx affordability

Featured icon alt text

88.5%

Percentage of members who spent less than $300 out-of-pocket (OOP) for prescriptions

Grandmother taking medication from pill organizer

$9.71

Average member OOP cost for 30 day supply

$32M

Value of PrudentRx Savings passed on to members

A doctor taking a patient's blood pressure

Setting a new standard for biosimilars in health care

We’re reimagining the pharmaceutical landscape to set a new standard for the adoption of biosimilar medications.